Trial to Evaluate the Management of Paroxysmal Supraventricular Tachycardia During an Electrophysiology Study With Tecadenoson | Zendy

Kenneth A. Ellenbogen | Zendy; Gearoid O’Neill | Zendy; Eric N. Prystowsky | Zendy; A. John Camm | Zendy; Lixin Meng | Zendy; Hsiao D. Lieu | Zendy; Markus Jerling | Zendy; Revati Shreeniwas | Zendy; Luiz Belardinelli | Zendy; Andrew A. Wolff | Zendy

Open Access

Trial to Evaluate the Management of Paroxysmal Supraventricular Tachycardia During an Electrophysiology Study With Tecadenoson

Author(s) -

Kenneth A. Ellenbogen,

Gearoid O’Neill,

Eric N. Prystowsky,

A. John Camm,

Lixin Meng,

Hsiao D. Lieu,

Markus Jerling,

Revati Shreeniwas,

Luiz Belardinelli,

Andrew A. Wolff

Publication year - 2005

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/circulationaha.104.510982

Subject(s) - medicine , placebo , anesthesia , bolus (digestion) , tachycardia , cardiology , alternative medicine , pathology

Tecadenoson is a potent selective A1-adenosine receptor agonist with a dose-dependent negative dromotropic effect on the AV node. Tecadenoson terminates induced paroxysmal supraventricular tachycardia (PSVT) without the clinically significant side effects caused by stimulation of other adenosine receptors. This trial was designed to determine a safe and effective tecadenoson bolus for termination of electrophysiologically induced PSVT.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research